• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg

    Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg

  2. European Commission Grants Marketing Authorization for Teva ’s CINQAERO® (reslizumab)

    European Commission Grants Marketing Authorization for Teva ’s CINQAERO® (reslizumab)

  3. Teva Completes Acquisition of Actavis Generics

    Teva Completes Acquisition of Actavis Generics

  4. Dr. Reddy’s Completes Acquisition of Product Portfolio from TEVA

    Dr. Reddy’s Completes Acquisition of Product Portfolio from TEVA

  5. Teva to buy Allergan's Anda Inc. distribution business for $500 mln

    Teva to buy Allergan's Anda Inc. distribution business for $500 mln

  6. Correction to Teva , Allergan Article

    Correction to Teva , Allergan Article

  7. Global Biosimilars Market Growth of 55.52% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Sandoz, Hospira, Teva Pharma - Research and Markets

    Global Biosimilars Market Growth of 55.52% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Sandoz, Hospira, Teva Pharma - Research and Markets

  8. Congress joins fight over rising cost of EpiPens as Shkreli defends

    Congress joins fight over rising cost of EpiPens as Shkreli defends

  9. UPDATE: Congress, Clinton join fight over rising cost of EpiPens as Shkreli defends

    UPDATE: Congress, Clinton join fight over rising cost of EpiPens as Shkreli defends

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.